Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Lipigon
Deal Size : Undisclosed
Deal Type : Acquisition
Lipigon Pharma buys LNAplus based antisense drug candidates from Secarna Pharma
Details : Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
March 23, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Lipigon
Deal Size : Undisclosed
Deal Type : Acquisition